Scholars Central

Conference abstractPublished 27 Oct 2015

Prion-like processing of pathological proteins as a unified basis for pharmaceutical development in neurodegenerative disorders

Authors: Claude M Wischik

TauRx Therapeutics, UK

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The molecular pathology of a number of different progressive neurodegenerative disorders are increasingly understood as driven by prion-like processing of an underlying misfolded protein. These now include Tau protein in AlzheimerâÂ?Â?s Disease (AD), Synuclein in ParkinsonâÂ?Â?s Disease (PD), TDP-43 in Frototemporal Dementia (FTD) and Amyotrophic Lateral Sclerosis, and Huntingtin in HuntingtonâÂ?Â?s Disease. Although the overt pathologies differ, there is a common underlying theme at the molecular level of a conformational change that converts a complex functional protein into an oligomeric form (low molecular weight aggregate) which has the capacity to go on recruiting the normal version of the protein into the pathological version. These oligomers are in effect self-replicating at the expense of the normal protein, leading both to loss of function and also to direct toxicity. The oligomers also behave as infectious particles able to propagate the process to otherwise healthy neurons. The abnormal conformation typically consists of a beta-sheet structure within the critical pathological binding domain. This characteristic conformation offers an opportunity for pharmaceutical intervention. A Tau Aggregation Inhibitor (LMTXÃ?®), originally developed for the treatment of Alzheimers Disease by selectively blocking the pathological tau-tau binding interaction, has a similar action on TDP-43 aggregates, on Synuclein aggregates and on Huntingtin aggregates. This opens the possibility of developing disease modifying drugs which are able to address a number of distinct neurodegenerative disorders by a common mechanism of action.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Alzheimers Disease & Parkinsonism
  • SubjectNeuroscience & Neurology
  • BylineArticles whose byline prints “Claude M Wischik”